Improving anti-melanoma effect of curcumin by biodegradable nanoparticles

Oncotarget

Volumn 8, Issue 65, 2017, Pages 108624-108642

  Wang, Bilan ^a,b,d   Liu, Xiaoxiao ^c,d   Teng, Yan ^b   Yu, Ting ^d   Chen, Junli ^b   Hu, Yuzhu ^d   Liu, Na ^b,e   Zhang, Lingli ^a,b,d   Shen, Yangmei ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

^d SICHUAN UNIVERSITY   (China)

^e Department of Pharmacy Puyang Medical College   (China)

Author keywords

Cell apoptosis; Curcumin; Melanoma; Micelles

Indexed keywords

CURCUMIN; MONOMETHYL POLY (ETHYLENE GLYCOL) POLY (LACTIDE) NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

A-375 CELL LINE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; B16 CELL LINE; CANCER TISSUE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MALE; MELANOMA; MICELLE; MOUSE; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE; TUMOR GROWTH;

EID: 85037688736     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.20585     Document Type: Article

References (44)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7-30. https://doi.org/10.3322/caac.21332
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66: 115-32. https://doi.org/10.3322/caac.21338
3. Kuk D, Shoushtari AN, Barker CA, Panageas KS, Munhoz RR, Momtaz P, Ariyan CE, Brady MS, Coit DG, Bogatch K, Callahan MK, Wolchok JD, Carvajal RD, et al. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. Oncologist. 2016; 21: 848-54. https://doi.org/10.1634/theoncologist.2015-0522
4. Rotte A, Bhandaru M, Zhou Y, McElwee KJ. Immunotherapy of melanoma: present options and future promises. Cancer Metastasis Rev. 2015; 34: 115-28. https://doi.org/10.1007/s10555-014-9542-0
5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-26. https://doi.org/10.1056/NEJMoa1104621
6. Pico de Coana Y, Choudhury A, Kiessling R. Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med. 2015; 21: 482-91. https://doi.org/10.1016/j.molmed.2015.05.005
7. Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs. 2014; 74: 1993-2013. https://doi.org/10.1007/s40265-014-0305-6
8. Ugurel S, Rohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, et al. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. Eur J Cancer. 2016; 53: 125-34. https://doi.org/10.1016/j.ejca.2015.09.013
9. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Jr., Lao CD, Linette GP, Thomas L, Lorigan P, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16: 375-84. https://doi.org/10.1016/S1470-2045(15)70076-8
10. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015; 6: 3479-92. https://doi.org/10.18632/oncotarget.2980
11. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, et al. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016; 2: 234-40. https://doi.org/10.1001/jamaoncol.2015.4368
12. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016; 54: 139-48. https://doi.org/10.1016/j.ejca.2015.11.016
13. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015; 26: 2375-91. https://doi.org/10.1093/annonc/mdv383
14. Quirk SK, Shure AK, Agrawal DK. Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. Transl Res. 2015; 166: 412-24. https://doi.org/10.1016/j.trsl.2015.06.005
15. Ahsan N, Mishra S, Jain MK, Surolia A, Gupta S. Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant alpha-Synuclein. Sci Rep. 2015; 5: 9862. https://doi.org/10.1038/srep09862
16. Banerjee S, Chakravarty AR. Metal complexes of curcumin for cellular imaging, targeting, and photoinduced anticancer activity. Acc Chem Res. 2015; 48: 2075-83. https://doi.org/10.1021/acs.accounts.5b00127
17. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014; 35: 3365-83. https://doi.org/10.1016/j.biomaterials.2013.12.090
18. Thangavel S, Yoshitomi T, Sakharkar MK, Nagasaki Y. Redox nanoparticles inhibit curcumin oxidative degradation and enhance its therapeutic effect on prostate cancer. J Control Release. 2015; 209: 110-9. https://doi.org/10.1016/j.jconrel.2015.04.025
19. Fetoni AR, Paciello F, Mezzogori D, Rolesi R, Eramo SL, Paludetti G, Troiani D. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer. 2015; 113: 1434-44. https://doi.org/10.1038/bjc.2015.359
20. Mosieniak G, Sliwinska MA, Przybylska D, Grabowska W, Sunderland P, Bielak-Zmijewska A, Sikora E. Curcumintreated cancer cells show mitotic disturbances leading to growth arrest and induction of senescence phenotype. Int J Biochem Cell Biol. 2016; 74: 33-43. https://doi.org/10.1016/j.biocel.2016.02.014
21. Yang X, Li Z, Wang N, Li L, Song L, He T, Sun L, Wang Z, Wu Q, Luo N, Yi C, Gong C. Curcumin-encapsulated polymeric micelles suppress the development of colon cancer in vitro and in vivo. Sci Rep. 2015; 5: 10322. https://doi.org/10.1038/srep10322
22. Ye M, Zhang J, Zhang J, Miao Q, Yao L, Zhang J. Curcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancer. Cancer Lett. 2015; 357: 196-205. https://doi.org/10.1016/j.canlet.2014.11.028
23. Seo JA, Kim B, Dhanasekaran DN, Tsang BK, Song YS. Curcumin induces apoptosis by inhibiting sarco/endoplasmic reticulum Ca2+ ATPase activity in ovarian cancer cells. Cancer Lett. 2016; 371: 30-7. https://doi.org/10.1016/j.canlet.2015.11.021
24. Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, Pinna F, Lee YH, Kitade M, Dominguez MP, Castven D, Breuhahn K, Conner EA, Galle PR, Andersen JB, Factor VM, et al. Curcumin effectively inhibits oncogenic NF-kappaB signaling and restrains stemness features in liver cancer. J Hepatol. 2015; 63: 661-9. https://doi.org/10.1016/j.jhep.2015.04.018
25. Hu A, Huang JJ, Li RL, Lu ZY, Duan JL, Xu WH, Chen XP, Fan JP. Curcumin as therapeutics for the treatment of head and neck squamous cell carcinoma by activating SIRT1. Sci Rep. 2015; 5: 13429. https://doi.org/10.1038/srep13429
26. Nagaraju GP, Zhu S, Ko JE, Ashritha N, Kandimalla R, Snyder JP, Shoji M, El-Rayes BF. Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. Cancer Lett. 2015; 357: 557-65. https://doi.org/10.1016/j.canlet.2014.12.007
27. Bortel N, Armeanu-Ebinger S, Schmid E, Kirchner B, Frank J, Kocher A, Schiborr C, Warmann S, Fuchs J, Ellerkamp V. Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB-and the beta-catenin pathways. Oncotarget. 2015; 6: 40680-91. https://doi.org/10.18632/oncotarget.5673
28. Sun M, Su X, Ding B, He X, Liu X, Yu A, Lou H, Zhai G. Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine (Lond). 2012; 7: 1085-100. https://doi.org/10.2217/nnm.12.80
29. Devassy JG, Nwachukwu ID, Jones PJ. Curcumin and cancer: barriers to obtaining a health claim. Nutr Rev. 2015; 73: 155-65. https://doi.org/10.1093/nutrit/nuu064
30. Wu H, Zhu L, Torchilin VP. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials. 2013; 34: 1213-22. https://doi.org/10.1016/j.biomaterials.2012.08.072
31. Zhang L, Chan JM, Gu FX, Rhee JW, Wang AZ, Radovic-Moreno AF, Alexis F, Langer R, Farokhzad OC. Selfassembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008; 2: 1696-702. https://doi.org/10.1021/nn800275r
32. Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG-a versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014; 192: 67-81. https://doi.org/10.1016/j.jconrel.2014.06.046
33. Zhang K, Tang X, Zhang J, Lu W, Lin X, Zhang Y, Tian B, Yang H, He H. PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications. J Control Release. 2014; 183: 77-86. https://doi.org/10.1016/j.jconrel.2014.03.026
34. Dordunoo SK, Oktaba AMC, Hunter W, Min W, Cruz T, Burt HM. Release of taxol from poly( γ-caprolactone) pastes: effect of water-soluble additives. Journal of Controlled Release. 1997; 44: 87-94. https://doi.org/10.1016/S0168-3659(96)01510-6
35. Park JS, Woo DG, Sun BK, Chung HM, Im SJ, Choi YM, Park K, Huh KM, Park KH. In vitro and in vivo test of PEG/PCL-based hydrogel scaffold for cell delivery application. J Control Release. 2007; 124: 51-9. https://doi.org/10.1016/j.jconrel.2007.08.030
36. Yang CS, Wu HC, Sun JS, Hsiao HM, Wang TW. Thermo-induced shape-memory PEG-PCL copolymer as a dual-drug-eluting biodegradable stent. ACS Appl Mater Interfaces. 2013; 5: 10985-94. https://doi.org/10.1021/am4032295
37. Dendukuri D, Hatton TA, Doyle PS. Synthesis and selfassembly of amphiphilic polymeric microparticles. Langmuir. 2007; 23: 4669-74. https://doi.org/10.1021/la062512i
38. Kale TS, Klaikherd A, Popere B, Thayumanavan S. Supramolecular assemblies of amphiphilic homopolymers. Langmuir. 2009; 25: 9660-70. https://doi.org/10.1021/la900734d
39. Gao X, Zheng F, Guo G, Liu XX, Fan R, Qian Z, Huang N, Wei Y. Improving the anti-colon cancer activity of curcumin with biodegradable nano-micelles. Journal of Materials Chemistry B. 2013; 1: 5778-90. https://doi.org/10.1039/C3TB21091J
40. Danafar H, Davaran S, Rostamizadeh K, Valizadeh H, Hamidi M. Biodegradable m-PEG/PCL Core-Shell Micelles: Preparation and Characterization as a Sustained Release Formulation for Curcumin. Adv Pharm Bull. 2014; 4: 501-10. https://doi.org/10.5681/apb.2014.074
41. Yallapu MM, Khan S, Maher DM, Ebeling MC, Sundram V, Chauhan N, Ganju A, Balakrishna S, Gupta BK, Zafar N, Jaggi M, Chauhan SC. Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer. Biomaterials. 2014; 35: 8635-48. https://doi.org/10.1016/j.biomaterials.2014.06.040
42. Wu GQ, Chai KQ, Zhu XM, Jiang H, Wang X, Xue Q, Zheng AH, Zhou HY, Chen Y, Chen XC, Xiao JY, Ying XH, Wang FW, et al. Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1. Oncotarget. 2016; 7: 26535-50. https://doi.org/10.18632/oncotarget.8532
43. Thilakarathna SH, Rupasinghe HP. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients. 2013; 5: 3367-87. https://doi.org/10.3390/nu5093367
44. Lin LC, Pai YF, Tsai TH. Isolation of Luteolin and Luteolin-7-O-glucoside from Dendranthema morifolium Ramat Tzvel and Their Pharmacokinetics in Rats. J Agric Food Chem. 2015; 63: 7700-6. https://doi.org/10.1021/jf505848z